The third most advanced product candidate in our generics pipeline is delayed release pantoprazole sodium, a generic version of the marketed drug Protonix®. This product is currently the subject of an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA) and is available for partnering.
Protonix® is a delayed-release capsule for oral administration that contains pantoprazole sodium. Protonix® inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome. According to Symphony Health Services, sales of pantoprazole sodium delayed-release tablets in the United States were approximately US$336 million for the 12 months ending January 2017 (TRx MBS Dollars).